Targeting SREBP1 chemosensitizes colorectal cancer cells to gemcitabine by caspase-7 upregulation

References

• Siegel R, Naishadham D. Jemal A: cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.
   Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.
   Google Scholar
• Papamichael D, Audisio RA, Glimelius B, et al. Treatment of colorectal cancer in older patients: international society of geriatric oncology (SIOG) consensus recommendations 2013. Ann Oncol. 2015;26:463–476.
   Google Scholar
• Markowitz SD, Bertagnolli MM. ESMO consensus guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. N Engl J Med. 2009;361:2449–2460.
   Google Scholar
• Schmoll HJ, Van Cutsem E, Stein A, et al. Cervantes A Molecular origins of cancer: molecular basis of colorectal cancer. Ann Oncol. 2012;23:2479–2516.
   Google Scholar
• Hua X, Wu J, Goldstein JL, et al. Structure of the human gene encoding sterol regulatory element binding protein-1 (SREBF1) and localization of SREBF1 and SREBF2 to chromosomes 17p11.2 and 22q13. Genomics. 1995;25:667–673.
   Google Scholar
• Edwards PA, Tabor D, Kast HR, et al. Regulation of gene expression by SREBP and SCAP. Biochim Biophys Acta. 2000;1529:103–113.
   Google Scholar
• Swinnen JV, Brusselmans K, Verhoeven G. Increased lipogenesis in cancer cells: new players, novel targets. Curr Opin Clin Nutr Metab Care. 2006;9:358–365.
   Google Scholar
• Yang YA, Morin PJ, Han WF, et al. Regulation of fatty acid synthase expression in breast cancer by sterol regulatory element binding protein-1c. Exp Cell Res. 2003;282:132–137.
   Google Scholar
• Ettinger SL, Sobel R, Akbari M, et al. Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res. 2004;64:2212–2221.
   Google Scholar
• Yahagi N, Shimano H, Hasegawa K, et al. Co-ordinate activation of lipogenic enzymes in hepatocellular carcinoma. Eur J Cancer. 2005;41:1316–1322.
   Google Scholar
• Calvisi DF, Wang C, Ho C, et al. Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. Gastroenterology. 2011;140:1071–1083.
   Google Scholar
• Yamashita T, Honda M, Takatori H, et al. Activation of lipogenic pathway correlates with cell proliferation and poor prognosis in hepatocellular carcinoma. J Hepatol. 2009;50:100–110.
   Google Scholar
• Li JN, Mahmoud MA, Han WF, et al. Sterol regulatory element-binding protein-1 participates in the regulation of fatty acid synthase expression in colorectal neoplasia. Exp Cell Res. 2000;261:159–165.
   Google Scholar
• Li X, Chen YT, Hu P, et al. Fatostatin displays high antitumor activity in prostate cancer by blocking SREBP-regulated metabolic pathways and androgen receptor signaling. Mol Cancer Ther. 2014;13:855–866.
   Google Scholar
• Zhou C, Qian W, Ma J, et al. Resveratrol enhances the chemotherapeutic response and reverses thestemness induced by gemcitabine in pancreatic cancer cells via targetingSREBP1. Cell Prolif. 2019;52:e12514.
   Google Scholar
• Passardi A, Fanini F, Turci L, et al. Prolonged pemetrexed infusion plus gemcitabine in refractory metastatic colorectal cancer: preclinical rationale and phase II study results. Oncologist. 2017;22:886–e79.
   Google Scholar
• Vena F, Li Causi E, Rodriguez-Justo M, et al. The MEK1/2 inhibitor pimasertib enhances gemcitabine efficacy in pancreatic cancer models by altering ribonucleotide reductase subunit-1 (RRM1). Clin Cancer Res. 2015;21:5563–5577.
   Google Scholar
• Isono M, Hoffmann MJ, Pinkerneil M, et al. Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine. J Exp Clin Cancer Res. 2017;36:1–12.
   Google Scholar
• Osborne TF, Espenshade PJ. Evolutionary conservation and adaptation in the mechanism that regulates SREBP action: what a long, strange tRIPit’s been. Genes Dev. 2009;23:2578–2591.
   Google Scholar
• Sato R, Yang J, Wang X, et al. Assignment of the membrane attachment, DNA binding, and transcriptional activation domains of sterol regulatory element-binding protein-1 (SREBP-1). J Biol Chem. 1994;269:17267–17273.
   Google Scholar
• Näär AM, Beaurang PA, Robinson KM, et al. Chromatin, TAFs, and a novel multiprotein coactivator are required for synergistic activation by Sp1 and SREBP-1a in vitro. Genes Dev. 1998;12:3020–3031.
   Google Scholar
• Shimano H. SREBPs: physiology and pathophysiology of the SREBP family. Febs J. 2009;276:616–621.
   Google Scholar
• Hagen RM, Rodriguez-Cuenca S, Vidal-Puig A. An allostatic control of membrane lipid composition by SREBP1. FEBS Lett. 2010;584:2689–2698.
   Google Scholar
• Perone Y, Farrugia AJ, Meira AR, et al. SREBP1 drives Keratin-80-dependent cytoskeletal changes and invasive behavior in endocrine-resistant ERα breast cancer. Nat Commun. 2019;10:2115.
   Google Scholar
• Zhou J, Qu G, Zhang G, et al. Glycerol kinase 5 confers gefitinib resistance throughSREBP1/SCD1 signaling pathway. J Exp Clin Cancer Res. 2019;38:96.
   Google Scholar
• Chen J, Yue J, Liu J, et al. Salvianolic acids improve liver lipid metabolism in ovariectomized rats via blocking STAT-3/SREBP1 signaling. Chin J Nat Med. 2018;16:838–845.
   Google Scholar
• Jeon TI, Osborne TF. SREBPs: metabolic integrators in physiology and metabolism. Trends Endocrinol Metab. 2012;23:65–72.
   Google Scholar
• Gibot L, Follet J, Metges JP, et al. Human caspase 7 is positively controlled by SREBP-1 and SREBP-2. BiochemJ. 2009;420:473–483.
   Google Scholar
• Lhoták S, Sood S, Carlisle RE, et al. ER stress contributes to renal proximal tubule injury by increasing SREBP-mediated lipid accumulation and apoptotic cell death. Am J Physiol Renal Physiol. 2012;303:F266–78.
   Google Scholar